Stock BRNS BARINTHUS BIOTHERAPEUTICS PLC
Add to a list
To use this feature you must be a member
Log inSign up

Financials Barinthus Biotherapeutics plc

Equities

BRNS

US91864C1071

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:30:01 2024-04-26 pm EDT 		5-day change 1st Jan Change
2.5 USD +2.93% Intraday chart for Barinthus Biotherapeutics plc -0.40% -32.25%
Apr. 18 Barinthus Cervical Lesions Treatment Study Meets Primary Objective -- Shares Rise After Hours MT
Apr. 18 BarinthuBarinthus Biotherapeutics plc Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus Infections CI

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Capitalization 1 387.5 87.65 142.3 97.3 - -
Enterprise Value (EV) 1 173.6 -91.54 16.91 -140.5 4.658 -43.32
P/E ratio -5.67 x 16.8 x -1.93 x -1.15 x -1.03 x -0.82 x
Yield - - - - - -
Capitalization / Revenue 1,446 x 1.96 x 177 x - - 76.4 x
EV / Revenue 648 x -2.05 x 21.1 x - - -34 x
EV / EBITDA -3.89 x -325 x -0.22 x 1.26 x -0.03 x 0.33 x
EV / FCF - - - - - -
FCF Yield - - - - - -
Price to Book 1.64 x 0.36 x 0.76 x 0.53 x 1.19 x 1.17 x
Nbr of stocks (in thousands) 34,879 37,297 38,565 38,921 - -
Reference price 2 11.11 2.350 3.690 2.500 2.500 2.500
Announcement Date 3/25/22 3/24/23 3/20/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net sales 1 4.82 0.268 44.7 0.802 - - 1.274
EBITDA 1 - -44.62 0.282 -78.51 -111.6 -134.7 -132.4
EBIT 1 - -45.22 -4.041 -83.91 -102.2 -122 -132.6
Operating Margin - -16,873.51% -9.04% -10,463.09% - - -10,404.24%
Earnings before Tax (EBT) 1 - -51.14 0.85 -76.52 -100 -123.6 -126.4
Net income 1 - -50.86 5.342 -73.35 -100 -123.6 -126.4
Net margin - -18,979.48% 11.95% -9,145.51% - - -9,916.1%
EPS 2 -692.2 -1.960 0.1400 -1.910 -2.172 -2.434 -3.050
Free Cash Flow - - - - - - -
FCF margin - - - - - - -
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share - - - - - - -
Announcement Date 3/23/21 3/25/22 3/24/23 3/20/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 0.019 - 15.02 17.06 6.165 6.457 0.468 0.334 - - - - - - -
EBITDA - - - - - - - - - - - - - - -
EBIT 1 -5.536 -16.67 0.654 13.79 7.553 -26.04 -21.48 -26.34 -16.1 -19.99 -24.62 -24.75 -25.25 -25.38 -
Operating Margin -29,136.84% - 4.35% 80.81% 122.51% -403.22% -4,590.6% -7,885.33% - - - - - - -
Earnings before Tax (EBT) 1 -4.577 -15.14 1.711 14.77 7.547 -23.18 -18.74 -24.96 -14.71 -18.11 -24.62 -24.75 -25.25 -25.38 -
Net income 1 -4.557 -15.11 2.596 15.69 8.242 -21.19 -18.18 -23.8 -14.07 -17.29 -24.62 -24.75 -25.25 -25.38 -
Net margin -23,984.21% - 17.29% 91.97% 133.69% -328.16% -3,884.62% -7,126.35% - - - - - - -
EPS 2 -0.1300 -0.3800 0.0680 0.4100 0.2200 -0.5500 -0.4800 -0.6200 -0.3700 -0.4500 -0.5387 -0.5423 -0.5290 -0.5633 -0.7100
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 11/12/21 3/25/22 5/11/22 8/9/22 11/10/22 3/24/23 5/12/23 8/10/23 11/9/23 3/20/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - -
Net Cash position 1 - 214 179 125 238 92.6 141
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow - - - - - - -
ROE (net income / shareholders' equity) - -34.8% 2.16% -34.1% -49.3% -76.4% -129%
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share 2 - 6.780 6.450 4.830 4.710 2.100 2.130
Cash Flow per Share - - - - - - -
Capex 1 - 1.15 - 5.41 2.2 2.4 2.7
Capex / Sales - 427.61% - 674.94% - - 211.9%
Announcement Date 3/23/21 3/25/22 3/24/23 3/20/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2.5 USD
Average target price
7.4 USD
Spread / Average Target
+196.00%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
BARINTHUS BIOTHERAPEUTICS PLC Stock Barinthus Biotherapeutics plc
-32.25% 97.3M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. BRNS Stock
  4. Financials Barinthus Biotherapeutics plc